Franklin Berger Net Worth

The estimated Net Worth of Franklin M Berger is at least $2.16 million dollars as of 16 June 2024. Mr. Berger owns over 33,150 units of Kezar Life Sciences Inc stock worth over $470,672 and over the last 20 years he sold KZR stock worth over $1,588,083. In addition, he makes $97,434 as Independent Director at Kezar Life Sciences Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Berger KZR stock SEC Form 4 insiders trading

Franklin has made over 36 trades of the Kezar Life Sciences Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 33,150 units of KZR stock worth $19,227 on 16 June 2024.

The largest trade he's ever made was selling 272,840 units of Kezar Life Sciences Inc stock on 14 December 2022 worth over $728,483. On average, Franklin trades about 15,100 units every 47 days since 2004. As of 16 June 2024 he still owns at least 811,503 units of Kezar Life Sciences Inc stock.

You can see the complete history of Mr. Berger stock trades at the bottom of the page.

Franklin Berger biography

Franklin M. Berger, CFA., is Independent Director of the Company. Mr. Berger worked at Sectoral Asset Management as a founder of the small-cap focused NEMO Fund from January 2007 through June 2008. Prior to that, he served at J.P. Morgan Securities, most recently as Managing Director, Equity Research and Senior Biotechnology Analyst and served in similar capacities at Salomon Smith Barney and Josephthal & Co. Mr. Berger has served as a member of the board of directors of Five Prime Therapeutics, Inc. since October 2014, Tocagen Inc. since October 2014, Bellus Health, Inc. since May 2010, ESSA Pharma, Inc. since March 2015, and Proteostasis Therapeutics, Inc. since February 2016. Mr. Berger previously served as a member of the board of directors BioTime, Inc., Seattle Genetics, Inc. and Immune Design Corp., each publicly held biotechnology companies.

What is the salary of Franklin Berger?

As the Independent Director of Kezar Life Sciences Inc, the total compensation of Franklin Berger at Kezar Life Sciences Inc is $97,434. There are 9 executives at Kezar Life Sciences Inc getting paid more, with John Fowler having the highest compensation of $3,532,020.

How old is Franklin Berger?

Franklin Berger is 70, he's been the Independent Director of Kezar Life Sciences Inc since 2016. There are no older and 14 younger executives at Kezar Life Sciences Inc.

What's Franklin Berger's mailing address?

Franklin's mailing address filed with the SEC is 225 FRANKLIN STREET, SUITE 2100, BOSTON, MA, 02110.

Insiders trading at Kezar Life Sciences Inc

Over the last 6 years, insiders at Kezar Life Sciences Inc have traded over $3,836,099 worth of Kezar Life Sciences Inc stock and bought 6,372,267 units worth $30,891,130 . The most active insiders traders include Venture Investments Ltd Mor..., Asset Management, Lp Chen B... et Franklin M Berger. On average, Kezar Life Sciences Inc executives and independent directors trade stock every 49 days with the average trade being worth of $91,954. The most recent stock trade was executed by Mark C. Schiller on 2 July 2024, trading 6,688 units of KZR stock currently worth $3,879.

What does Kezar Life Sciences Inc do?

kezar life sciences, inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the united states. the company's lead product candidate is kzr-616, a selective immunoproteasome inhibitor that is in phase 2 clinical trials across five autoimmune indications, including lupus nephritis, autoimmune hemolytic anemia, immune thrombocytopenia, dermatomyositis, and polymyositis; and phase 1b/2 clinical trials in systemic lupus erythematosus and lupus nephritis. its preclinical products include kzr-616, a selective immunoproteasome inhibitor for the treatment of various autoimmune disease indications; and kzr-tbd for the treatment of oncology and autoimmunity. the company was founded in 2015 and is headquartered in south san francisco, california.

Complete history of Mr. Berger stock trades at Essa Pharma Inc, Five Prime Therapeutics Inc, Proteostasis Therapeutics Inc, Seagen Inc, Tocagen, Kezar Life Sciences Inc, Atreca Inc et Atea Pharmaceuticals

Kezar Life Sciences Inc executives and stock owners

Kezar Life Sciences Inc executives and other stock owners filed with the SEC include:

• John Fowler,
  Chief Executive Officer, Director
• Christopher Kirk,
  President, Chief Scientific Officer, Director
• Marc Belsky,
  Chief Financial Officer, Secretary
• John Franklin Fowler,
  Co-Founder, CEO & Director
• Dr. Noreen Roth Henig,
  Chief Medical Officer
• Dr. Christopher J. Kirk,
  Co-Founder, Pres, Chief Scientific Officer & Director
• Jean-Pierre Sommadossi,
  Independent Chairman of the Board
• Graham Cooper,
  Independent Director
• Michael Kauffman,
  Independent Director
• Franklin Berger,
  Independent Director
• Jason Dinges,
  Independent Director
• Elizabeth Garner,
  Independent Director
• Alex Gray,
  IR Contact Officer
• Noreen Henig,
  Chief Medical Officer
• Vassiliki Economides,
  Senior Vice President - Strategy and External Affairs
• Vassiliki Economides,
  Sr. VP of Strategy & External Affairs
• Gitanjali Jain,
  VP of Investor Relations & External Affairs
• Michael Wolfe,
  Director of Fin. & Operations
• Marc L. Belsky,
  CFO & Sec.
• Dr. Jack Taunton Ph.D.,
  Co-Founder
• Talent Investments Ltd Equal,
  10% owner
• Management Company, Llc Abe...,
  10% owner
• Arthur Ma.M. Pappas Life Sc...,
  
• Fund Iv, L.P.Omega Fund Iv ...,
  
• Asset Management, Lp Chen B...,
  
• Venture Investments Ltd Mor...,
  
• Ventures, Inc.Chiesi Ventur...,
  
• Therapeutics, Inc.Amgen Inc...,
  
• City Capital Llc Bay,
  10% owner
• Thomas F Steyer,
  
• Niti Goel,
  Chief Medical Officer
• Mark C. Schiller,
  Chief Legal Officer
• Nicholas Michael Mordwinkin,
  Chief Business Officer
• Micki Klearman,
  
• Courtney Wallace,